Brainomix, the AI-powered medtech solutions company, today announced its collaboration with the National Consortium of Intelligent Medical Imaging (NCIMI, hosted at the University of Oxford) and three selected NHS sites on a project to optimize and validate its automated cancer tracking tool, e-ACT.
- 12-month study at three NHS cancer centres to evaluate AI-enable e-ACT product for automated assessment of disease progression and treatment response in lung cancer patients compared to radiologists
OXFORD, UK, 10 October 2022 – Brainomix, the AI-powered medtech solutions company, today announced its collaboration with the National Consortium of Intelligent Medical Imaging (NCIMI, hosted at the University of Oxford) and three selected NHS sites on a project to optimize and validate its automated cancer tracking tool, e-ACT.
e-ACT measures the size of lung cancer tumors and detects changes in tumor size indicating treatment response and disease progression. The collaboration will evaluate how automated assessment using e-ACT compares with the observations of medical specialists.
Preliminary data has already shown that e-ACT is at least as good as specialist doctors in measuring the size of lung cancer tumors at a single time point. This project, with NCIMI and NHS sites in Truro, Bath and Leeds, will allow Brainomix to develop e-ACT and demonstrate the potential impact that technology has to improve care of patients with cancer.
Lung cancer is the third most common cancer in the UK, and the leading cause of cancer-related death. Despite therapeutic advances over the past few decades, 60% of patients diagnosed with lung cancer die within the first year, and only 16% survive past 5 years.
Lung cancer treatment decisions are managed by multidisciplinary teams (MDTs), who monitor treatment response and disease progression by assessing CT scans over time, with a particular focus on tumor growth. This information is used to determine the efficacy of treatment(s), and whether a different treatment may be needed, or even that therapy should be stopped.
The 12-month study will include CT (CAT) scans and clinical data from 200 patients with confirmed lung cancer on systematic therapy. The study team will evaluate how automated assessment of disease progression and treatment response using e-ACT compares to radiologist assessment. The study will also include descriptive analysis of tumor dynamics using e-ACT in a representative NHS cohort.
This new project builds on a previous successful collaboration between NCIMI and Brainomix in the stroke space.
Dr Michalis Papadakis, CEO and co-founder of Brainomix said, “We are excited to embark on this project, and thank NCIMI for their ongoing support. The preliminary results for e-ACT are very promising. With this new collaboration we have an opportunity to elevate the level of validation and refinement using a broad and robust dataset, which will bring e-ACT closer to a tool which improves clinical decision making and further personalizes care for cancer patients.”
Mark Beggs, COO at NCIMI said, “We are delighted that this second Brainomix project has started. Both teams have worked effectively to secure ethical approval and to ensure contracts are in place. This study builds on the existing relationships with Royal Cornwall, Leeds and Bath NHS Trusts who have been great contributors to other NCIMI projects. We are especially pleased that Brainomix can build on the success of its e-Stroke product and expand into new therapeutic areas. We are looking forward to seeing early progress with the e-ACT project.”
Click here to learn more about Brainomix’s e-ACT software.
-ENDS-
About Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning imaging biomarkers and software solutions that are used in more than 30 countries worldwide. Its first product, the e-Stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients. Its pipeline includes novel imaging biomarkers for better treatment of lung fibrosis and cancer, and its technology is being used by pharmaceutical companies to improve clinical trial success.
A private company, with headquarters in Oxford, UK Brainomix’s investors include Boehringer Ingelheim Venture Fund, Parkwalk Advisors, Tencent Holdings and Oxford University Innovation Fund.
To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.
About the National Consortium of Intelligent Medical Imaging (NCIMI)
About NCIMI
NCIMI’s mission is to integrate medical imaging, such as CT and MRI scans, with artificial intelligence and machine learning to improve patient care by transforming how medical professionals diagnose diseases and chronic conditions. By bringing this information together, and by engaging with patients to gather anonymised data, we can speed up and improve how we diagnose and prevent diseases whilst lowering costs – improving treatment options for patients. Based at University of Oxford’s Big Data Institute, NCIMI brings together more than 25 partners including NHS trusts, medical tech companies, charities and patient groups. NCIMI was funded by Innovate UK in 2019 through the Industrial Strategy Challenge Fund’s drive to support the UK’s AI sector
Contacts
At Brainomix
Jeff Wyrtzen, Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730
Media enquiries (Brainomix)
Charles Consultants
Sue Charles - Sue@charles-consultants.com
M +44 (0)7968 726585
Media enquiries (NCIMI)
Agile PR
Lyssa-Fee Crump - lyssa@theagilepr.co.uk
Rachel Picken - rachel@theagilepr.co.uk
M +44 (0)7761 765999